Investment Thesis
Jupiter Neurosciences exhibits critical financial distress with negative stockholders' equity of -$2.8M (technical insolvency), severe liquidity crisis (current ratio 0.51x), and an unsustainable burn rate of $1.4M per period with only $2.4M cash remaining. Minimal revenue of $18.7K with zero YoY growth and accelerating losses indicate the company lacks commercial traction and faces imminent solvency concerns absent immediate capital infusion.
Strengths
- Maintains $2.4M in cash reserves providing 1.7-2 periods of operational runway
- No long-term debt obligations on balance sheet
- Gross margin of 76.6% demonstrates potential economics if commercial success achieved
Risks
- Negative stockholders' equity of -$2.8M: liabilities exceed assets by $2.8M indicating technical insolvency
- Critical liquidity crisis with current ratio 0.51x unable to cover short-term obligations
- Operating cash burn of -$1.4M per period with only 1.7-2 periods of cash runway at current burn rate
- Revenue stagnant at $18.7K with 0% YoY growth indicating failed commercialization and pipeline challenges
- Net income declining 254% YoY demonstrating rapid financial deterioration
- Zero insider Form 4 activity in past 90 days suggesting management lacks confidence in turnaround
- As early-stage biotech, survival dependent on successful capital raise; failed clinical or regulatory outcomes would be fatal
Key Metrics to Watch
- Cash balance and burn rate trend - determines runway until next capital raise necessity
- Revenue growth trajectory - any signs of commercial traction or contract wins
- Operating loss trend - whether burn rate is accelerating or stabilizing
- Stockholders' equity recovery - ability to return to positive equity position
- Capital raises and dilution - terms of survival funding will heavily dilute existing shareholders
Financial Metrics
Revenue
18.7K
Net Income
-2.1M
EPS (Diluted)
$-0.06
Free Cash Flow
-1.4M
Total Assets
3.9M
Cash
2.4M
Profitability Ratios
Gross Margin
76.6%
Operating Margin
-10,524.3%
Net Margin
-11,054.9%
ROE
N/A
ROA
-52.2%
FCF Margin
-7,678.0%
Balance Sheet & Liquidity
Current Ratio
0.51x
Quick Ratio
0.48x
Debt/Equity
N/A
Debt/Assets
170.5%
Interest Coverage
-16.55x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:39:11.791865 |
Data as of: 2026-03-31 |
Powered by Claude AI